• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Abbott, Novo Nordisk ink deal for digital diabetes tools

February 20, 2019 By Sarah Faulkner

Abbott, Novo Nordisk partnershipAbbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system.

The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as make more informed treatment decisions.

Neither Abbott nor Novo Nordisk disclosed when this feature would be available for users. Instead, they said that they are “working hard to bring these integrated solutions to patients as soon as possible.”

“Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,” Anders Dyhr Toft, corporate VP of commercial innovation at Novo Nordisk, said in prepared remarks. “Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient′s individual diabetes management and can help people with diabetes feel more confident in their treatment.”

“It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,” Jared Watkin, SVP of Abbott’s diabetes care division, added.

“Diabetes is a time intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life,” Watkin said.

In November last year, Abbott won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system.

The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had to use a separate device to connect data from the sensor to their phones.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals, Wall Street Beat Tagged With: abbott, Novo Nordisk

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS